Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial

Last updated: June 28, 2021
Sponsor: Chang Gung Memorial Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Esophageal Cancer

Esophageal Disorders

Squamous Cell Carcinoma

Treatment

N/A

Clinical Study ID

NCT03713749
201800322A3C601
  • Ages 18-80
  • All Genders

Study Summary

The investigators will assess the adequacy of nodal dissection along the recurrent laryngeal nerve performed with robot-assisted versus video-assisted thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma through a prospective multicentre randomized study design.

Eligibility Criteria

Inclusion

Inclusion criteria

  1. Age between 18~80

  2. Histologically proven primary intrathoracic esophageal squamous cell carcinoma and will undergo McKeown MIE and bilateral RLN LND.

  3. Patients should have a performance status 0, 1 or 2 according to the European Clinical Oncology Group.

  4. Surgical resectable(cT14a, N03, M0)

  5. Written informed consent

Exclusion criteria are

  1. Previous major thoracic surgery rendering minimal invasive approach unfeasible

  2. prognosis determining malignancy other than esophageal cancer, inability to undergo curative resection and/or follow-up

  3. inability to provide oral or written informed consent.

  4. pre-existed vocal cord dysfunction will also be excluded.

Study Design

Total Participants: 212
Study Start date:
October 22, 2018
Estimated Completion Date:
December 22, 2022

Study Description

Radical lymph node dissection (LND) along the recurrent laryngeal nerve (RLN) is surgically demanding and can be associated with substantial postoperative morbidity. The question as to whether robot-assisted esophagectomy (RE) might be superior to video-assisted thoracoscopic esophagectomy (VATE) for performing LND along the RLN in patients with esophageal squamous cell carcinoma (ESCC) remains open.

The investigators will conduct a multicenter, open-label, randomized controlled trial (termed REVATE) enrolling patients with ESCC scheduled to undergo LND along the RLN. Patients will be randomly assigned to either RE or VATE. The primary outcome measure will be the rate of unsuccessful LND along the left RLN, which will be defined as 1) failure to remove lymph nodes along the left RLN or 2) occurrence of left RLN palsy following LND. Secondary outcomes will include the number of successfully removed RLN nodes, postoperative recovery, length of hospital stay, 30- and 90-day mortality, quality of life, and oncological outcomes.

Connect with a study center

  • Chang Gung memorial hospital-Linkou

    Taoyuan, 333
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.